ORBi: Detailled Reference

Article (Scientific journals)

Inhibiteur des SGLT2 ou analogue du GLP-1 chez un patient diabetique avec maladie cardiovasculaire ?

Scheen, André; Paquot, Nicolas

2018 • In Revue Médicale Suisse, 14 (615), p. 1460-1465

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/229853

PubMed
30136462

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2018 RMS Inhibiteur des SGLT2 RMS_615_1460.pdf

Publisher postprint (4.41 MB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Sodium-glucose cotransporter type 2 inhibitors (SGLT2is), with empagliflozin in EMPA-REG OUTCOME, and glucagon-like peptide-1 receptor agonists (GLP-1RAs), with liraglutide in LEADER, have proven their ability to reduce major cardiovascular events and mortality in patients with type 2 diabetes and established cardiovascular disease. Thus clinicians have to choose between the two options in patients at high risk. The choice should be based upon a personalized approach, which has to take into account the drug properties, especially the tolerance profile, and patient's individual characteristics. In patients with heart failure, the added value of a SGLT2i appears obvious while in those with advanced renal insufficiency, current evidence favours the use of a GLP-1RA.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Cardiovascular & respiratory systems

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques

Language :

French

Title :

Inhibiteur des SGLT2 ou analogue du GLP-1 chez un patient diabetique avec maladie cardiovasculaire ?

Alternative titles :

[en] SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?

Publication date :

2018

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

14

Issue :

615

Pages :

1460-1465

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 04 December 2018

Statistics

Number of views

324 (4 by ULiège)

Number of downloads

590 (3 by ULiège)

More statistics

Scopus citations^®

6

Scopus citations^®
without self-citations

0

OpenAlex citations

1

Bibliography

Scheen AJ. Pharmacological management of type 2 diabetes: what's new in 2017 ? Expert Rev Clin Pharmacol 2017;10:1383-94.
Thompson PL, Davis TME. Cardiovascular effects of glucose-lowering therapies for type 2 diabetes: new drugs in perspective. Clin Ther 2017;39:1012-25.
Roder ME. Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. Ther Adv Chronic Dis 2018;9:33-50.
Ahmed HM, Khraishah H, Cho L. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. Eur Heart J 2018;39:2368-75.
Abdul-Ghani M, DeFronzo RA, Del Prato S, et al. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived ? Diabetes Care 2017;40:813-20.
Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist thera: a complementary approach to the treatment of type 2 diabetes. Postgrad Med 2017;129:686-97.
DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 2017;19:1353-62.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
Scheen AJ, Ernest P, Jandrain B. Protection cardio-rénale par les inhibiteurs des SGLT2 (gliflozines): d'EMPA-REG OUTCOME à CANVAS. Rev Med Suisse 2017;13:1421-6.
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526-34.
Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 2018;39:363-70.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
Raz I, Mosenzon O, Bonaca MP, et al. DECLARE-TIMI 58: participants' baseline characteristics. Diabetes Obes Metab 2018;20:1102-10.
Birkeland KI, Jorgensen ME, Carsten-sen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 2017;5:709-17.
Persson F, Nystrom T, Jorgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in type 2 diabetes patients (CVD-REAL Nordic) when compared to DPP-4 inhibitor: a multinational observational study. Diabetes Obes Metab 2018;20:344-51
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
Scheen AJ, Wallemacq C, Jandrain B, et al. Protection cardiovasculaire du patient diabétique de type 2: d’EMPA-REG OUTCOME à LEADER. Rev Med Suisse 2016;12:1370-5.
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44.
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228-39.
Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018;6:105-13.
Scheen AJ. GLP-1 receptor agonists and cardiovascular protection. Class effect or not ? Diabetes Metab 2018;44:193-6.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 2018;41:S73-85.
Darmon P, Bauduceau B, Bordier L, et al. Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l’hyperglycémie du patient diabétique de type 2. Médecine des Maladies métaboliques 2017;11:577-93.
Gurgle HE, White KMc, Adam-Marx C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag 2016;12:239-49.
Consoli A, Formoso G, Baldassarre MPA, et al. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf 2018;17:293-302.
d'Emden M, Amerena J, Deed G, et al. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. Diabetes Res Clin Pract 2018;136:23-31.
Suissa S. Mortality reduction in EMPA-REG OUTCOME trial: beyond the antidiabetes effect. Diabetes Care 2018;41:219-23.
Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab 2017;43(Suppl. 1) 2S13-2S9.
Butler J, Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 2017;19:1390-400.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
Seferovic PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:853-72.
Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018;137:119-29.
Scheen AJ. SGLT2 inhibitors: benefit/risk balance. Curr Diabetes Rep 2016;16:92.
Scheen AJ. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 2015;14:1879-904.
Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 2018;122:1439-59.
Scheen AJ. Does lower-limb amputation concern all SGLT-2 inhibitors ? Nature Rev Endocrinol 2018;14:326-8.
Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2016;19:524-36.

Similar publications